Skip to content
2000
Volume 20, Issue 2
  • ISSN: 1566-5232
  • E-ISSN: 1875-5631

Abstract

CD24, is a mucin-like GPI-anchored molecules. By immunohistochemistry, it is widely detected in many solid tumors, such as breast cancers, genital system cancers, digestive system cancers, neural system cancers and so on. The functional roles of CD24 are either fulfilled by combination with ligands or participate in signal transduction, which mediate the initiation and progression of neoplasms. However, the character of CD24 remains to be intriguing because there are still opposite voices about the impact of CD24 on tumors. In preclinical studies, CD24 target therapies, including monoclonal antibodies, target silencing by RNA interference and immunotherapy, have shown us brighten futures on the anti-tumor application. Nevertheless, evidences based on clinical studies are urgently needed. Here, with expectancy to spark new ideas, we summarize the relevant studies about CD24 from a tumor perspective.

Loading

Article metrics loading...

/content/journals/cgt/10.2174/1566523220666200623170738
2020-04-01
2025-09-04
Loading full text...

Full text loading...

/content/journals/cgt/10.2174/1566523220666200623170738
Loading

  • Article Type:
    Review Article
Keyword(s): cancer; CD24; granulocytes; immunotherapy; lymphocytes; mAb
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test